Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · 2025
DOI: 10.5387/fms.25-00013 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2025. Verfasst von Naoya Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, Chemoradiotherapy, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE: Neoadjuvant pancreatic ductal adenocarcinoma (PDAC) treatment is evolving, and chemoradiotherapy (CRT) is emerging as a promising strategy for neoadjuvant therapy. Given the variability in radiotherapy protocols, this study aimed to evaluate the feasibility and safety of gemcitabine-based neoadjuvant chemoradiotherapy. METHODS: In this single-arm, phase 1 clinical trial, 31 patients with PDAC were enrolled between April 2016 and August 2019. All patients received preoperative gemcitabine-based chemoradiotherapy with adverse events as the primary endpoint. Multichannel radiation was administered at a total dose of 54 Gy in daily fractions of 1.8 Gy (five fractions per week), which represents a novel aspect of this study. RESULTS: Neoadjuvant therapy was completed in 24 patients, while seven were discontinued due to disease progression. The common adverse events included leukopenia (48.3%), thrombocytopenia (12.9%), and anemia (3.2%). Among the patients who underwent pancreatectomy, the R0 resection rate was 95.8%. Intention-to-treat analysis indicated a 2-year overall survival rate of 49.8% and a 2-year recurrence-free survival rate of 42.4%. High pretreatment CA19-9 levels were identified as predictive factors for overall survival (HR = 28.7, 95% CI:5.00-164.3). CONCLUSIONS: Gemcitabine-based neoadjuvant chemoradiotherapy is a feasible and effective approach for achieving high R0 resection rates in resectable and borderline PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University.
Zitieren
APA
Sato, N., Kenjo, A., Ishigame, T., Kofunato, Y., Haga, J., Muto, M., Tsukida, S., Chiba, H., Azuma, T., Kimura, T., & Marubashi, S. (2025). Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. https://doi.org/10.5387/fms.25-00013
Vancouver
Sato N, Kenjo A, Ishigame T, Kofunato Y, Haga J, Muto M, et al. Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study. FUKUSHIMA JOURNAL OF MEDICAL SCIENCE. 2025. doi:10.5387/fms.25-00013
BibTeX
@article{Sato2025,
author = {Sato, Naoya and Kenjo, Akira and Ishigame, Teruhide and Kofunato, Yasuhide and Haga, Junichiro and Muto, Makoto and Tsukida, Shigeyuki and Chiba, Hiroto and Azuma, Takayasu and Kimura, Takashi and Marubashi, Shigeru},
title = {Evaluating preoperative gemcitabine-based chemoradiation for resectable and borderline resectable pancreatic cancer: a phase 1 study},
journal = {FUKUSHIMA JOURNAL OF MEDICAL SCIENCE},
year = {2025},
doi = {10.5387/fms.25-00013}
}
EUVIMED